Pomerantz Law Firm Initiates Class Action Lawsuit Against Altimmune, Inc. Amid Concerns Over Securities Fraud
On September 18, 2025, the Pomerantz Law Firm announced a significant class action lawsuit against Altimmune, Inc., a company listed on NASDAQ under the symbol ALT. This legal action primarily addresses allegations surrounding securities fraud and potential unlawful business practices associated with the company. Investors who may have suffered losses due to their investments in Altimmune are being encouraged to join this class action lawsuit.
Danielle Peyton of Pomerantz urges any affected investor to contact her directly at [email protected] or through the toll-free hotline at 888-4-POMLAW. Those interested in participating should provide their mailing address, contact number, and details about their share acquisitions.
The concern stems from findings regarding Altimmune's operations, particularly a letdown associated with the results from a recent Phase 2b MASH trial of Pemvidutide, announced on June 26, 2025. Despite Altimmune's promotional expectations leading up to these results, the trial failed to achieve statistical significance in its primary endpoint — fibrosis reduction. The unexpected higher response rate in the placebo group contributed to this shortfall—an issue that Altimmune's officials addressed with apparent indifference, characterizing the results as typical for the early trial phase with hopes for better outcomes in a subsequent Phase 3 trial.
Following this press release, a sharp decline in Altimmune's stock was observed, plummeting $4.10 per share, equivalent to a staggering 53.2%, leaving the stock price at $3.61. Such drastic movements in share price are alarming and highlight the potential risk factors investors must consider.
Pomerantz LLP is recognized in the legal community as one of the foremost law firms specializing in corporate and securities litigation, with a rich history founded by the late Abraham L. Pomerantz. They have a reputation for advocating on behalf of victims in cases involving securities fraud and other corporate misconduct. With offices around the world, the firm is committed to securing substantial damages for class members affected by such malpractice.
Investors who purchased or acquired Altimmune securities during the defined Class Period have until October 6, 2025, to petition the court for lead plaintiff status. Detailed documentation regarding the lawsuit, including a full copy of the complaint, can be accessed through the firm’s webpage at www.pomerantzlaw.com.
Given the circumstances and substantial implications surrounding this case, investors are urged to take prompt action to understand their legal options and consider joining the class action. Investors have the right to seek justice and recovery for their financial losses. As the lawsuit progresses, updates are expected that may shed further light on the company's practices and any potential resolutions for the claimants. Stakeholders and observers will undoubtedly be watching this case closely as it unfolds, given the considerable attention it has drawn in the investment community.
Danielle Peyton of Pomerantz urges any affected investor to contact her directly at [email protected] or through the toll-free hotline at 888-4-POMLAW. Those interested in participating should provide their mailing address, contact number, and details about their share acquisitions.
The concern stems from findings regarding Altimmune's operations, particularly a letdown associated with the results from a recent Phase 2b MASH trial of Pemvidutide, announced on June 26, 2025. Despite Altimmune's promotional expectations leading up to these results, the trial failed to achieve statistical significance in its primary endpoint — fibrosis reduction. The unexpected higher response rate in the placebo group contributed to this shortfall—an issue that Altimmune's officials addressed with apparent indifference, characterizing the results as typical for the early trial phase with hopes for better outcomes in a subsequent Phase 3 trial.
Following this press release, a sharp decline in Altimmune's stock was observed, plummeting $4.10 per share, equivalent to a staggering 53.2%, leaving the stock price at $3.61. Such drastic movements in share price are alarming and highlight the potential risk factors investors must consider.
Pomerantz LLP is recognized in the legal community as one of the foremost law firms specializing in corporate and securities litigation, with a rich history founded by the late Abraham L. Pomerantz. They have a reputation for advocating on behalf of victims in cases involving securities fraud and other corporate misconduct. With offices around the world, the firm is committed to securing substantial damages for class members affected by such malpractice.
Investors who purchased or acquired Altimmune securities during the defined Class Period have until October 6, 2025, to petition the court for lead plaintiff status. Detailed documentation regarding the lawsuit, including a full copy of the complaint, can be accessed through the firm’s webpage at www.pomerantzlaw.com.
Given the circumstances and substantial implications surrounding this case, investors are urged to take prompt action to understand their legal options and consider joining the class action. Investors have the right to seek justice and recovery for their financial losses. As the lawsuit progresses, updates are expected that may shed further light on the company's practices and any potential resolutions for the claimants. Stakeholders and observers will undoubtedly be watching this case closely as it unfolds, given the considerable attention it has drawn in the investment community.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.